FIA
NMTC icon

FNY Investment Advisers’s NeuroOne Medical Technologies NMTC Stock Holding History

FNY Investment Advisers’s Portfolio NMTC Stock Details NMTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-333
Closed -$3K – 642
2023
Q1 		$3K Buy
+333
New +$3.08K ﹤0.01% 442

Other funds holding NMTC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PGAM
Princeton Global Asset Management Princeton, New Jersey $698M AUM 31.09% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

FNY Investment Advisers's NMTC Position: Q2 2023 in Review

FNY Investment Advisers sold out of NeuroOne Medical Technologies (NMTC) in Q2 2023, closing a stake of 333 shares — an estimated $3K sold.

FNY Investment Advisers first reported a position in NMTC in Q1 2023 and held it in 1 quarter. The position peaked at $3K in Q1 2023. 14 funds tracked by Wall St. Rank hold NMTC as of Q2 2023.

  • FNY Investment Advisers reported no remaining NeuroOne Medical Technologies position as of Q2 2023 after selling out during the quarter.
  • FNY Investment Advisers sold 333 NeuroOne Medical Technologies shares in Q2 2023, an estimated $3K.
  • FNY Investment Advisers first reported a position in NeuroOne Medical Technologies in Q1 2023 and held it in 1 quarter.
  • FNY Investment Advisers's NeuroOne Medical Technologies position peaked at $3K in Q1 2023.
  • 14 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q2 2023.

Based on FNY Investment Advisers's 13F filing for Q2 2023, filed 11 Jul 2023.